Skip to main content

Table 1 Associations of genetic proxies for antihypertensive drugs with eGFR in a meta-analysis of the UK Biobank and CKDGen

From: Using Mendelian randomization study to assess the renal effects of antihypertensive drugs

Class

#SNPs

Beta

95% CI

p

ACE inhibitors

1

0.06

0.008, 0.11

0.02

ARBs

1

−0.02

− 0.10, 0.06

0.65

CCBs

9

−0.0001

−0.03, 0.03

0.99

Alpha-adrenoceptor blockers

6

−0.004

−0.03, 0.02

0.73

Adrenergic neuron blockers

3

−0.01

−0.06, 0.03

0.61

Beta-adrenoceptor blockers

7

−0.02

−0.04, − 0.004

0.02

Centrally acting antihypertensives

4

−0.01

−0.09, 0.07

0.86

Loop diuretics

2

0.05

0.004, 0.09

0.03

PSDs and aldosterone antagonists

4

−0.03

−0.07, 0.005

0.09

Renin inhibitors

1

−0.003

−0.07, 0.06

0.92

Thiazides and related diuretics

4

−0.03

−0.08, 0.01

0.12

Vasodilator antihypertensives

8

−0.01

−0.03, 0.02

0.57

  1. Beta is the beta-coefficient with eGFR per effect size (standard deviation) of systolic blood pressure
  2. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate; PSD, potassium-sparing diuretic